Is Lexeo Therapeutics, Stock a Good Investment?
Lexeo Therapeutics, Investment Advice | LXEO |
- Examine Lexeo Therapeutics,'s financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Lexeo Therapeutics,'s leadership team and their track record. Good management can help Lexeo Therapeutics, navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Lexeo Therapeutics,'s business and its evolving consumer preferences.
- Compare Lexeo Therapeutics,'s performance and market position to its competitors. Analyze how Lexeo Therapeutics, is positioned in terms of product offerings, innovation, and market share.
- Check if Lexeo Therapeutics, pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Lexeo Therapeutics,'s stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Lexeo Therapeutics, Common stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Lexeo Therapeutics, Common is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Unstable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Lexeo Therapeutics, Stock
Researching Lexeo Therapeutics,'s stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.13. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Lexeo Therapeutics, recorded a loss per share of 2.78. The entity had not issued any dividends in recent years.
To determine if Lexeo Therapeutics, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Lexeo Therapeutics,'s research are outlined below:
| Lexeo Therapeutics, generated a negative expected return over the last 90 days | |
| Lexeo Therapeutics, has high historical volatility and very poor performance | |
| Net Loss for the year was (98.33 M) with loss before overhead, payroll, taxes, and interest of (74.09 M). | |
| Lexeo Therapeutics, generates negative cash flow from operations | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Lexeo Therapeutics Announces Quarterly Earnings Results |
Lexeo Therapeutics, Quarterly Cost Of Revenue |
|
Lexeo Therapeutics, uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Lexeo Therapeutics, Common. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Lexeo Therapeutics,'s previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of November 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of November 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Lexeo Therapeutics,'s stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Lexeo Therapeutics,'s investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-03-11 | 2023-12-31 | -0.73 | -0.85 | -0.12 | 16 | ||
2024-11-13 | 2024-09-30 | -0.6681 | -0.89 | -0.2219 | 33 | ||
2023-12-11 | 2023-09-30 | -2.6 | -12.36 | -9.76 | 375 |
Lexeo Therapeutics, Target Price Consensus
Lexeo target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Lexeo Therapeutics,'s target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 7 | Strong Buy |
Most Lexeo analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Lexeo stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Lexeo Therapeutics,, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationLexeo Therapeutics, Target Price Projection
Lexeo Therapeutics,'s current and average target prices are 4.11 and 22.43, respectively. The current price of Lexeo Therapeutics, is the price at which Lexeo Therapeutics, Common is currently trading. On the other hand, Lexeo Therapeutics,'s target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Lexeo Therapeutics, Market Quote on 27th of March 2025
Target Price
Analyst Consensus On Lexeo Therapeutics, Target Price
Lexeo Therapeutics, Analyst Ratings
Lexeo Therapeutics,'s analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Lexeo Therapeutics, stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Lexeo Therapeutics,'s financials, market performance, and future outlook by experienced professionals. Lexeo Therapeutics,'s historical ratings below, therefore, can serve as a valuable tool for investors.Lexeo Therapeutics,'s market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 146.86 M.Market Cap |
|
Lexeo Therapeutics,'s profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.67) | (0.70) | |
| Return On Capital Employed | (0.64) | (0.67) | |
| Return On Assets | (0.67) | (0.70) | |
| Return On Equity | (0.84) | (0.80) |
Determining Lexeo Therapeutics,'s profitability involves analyzing its financial statements and using various financial metrics to determine if Lexeo Therapeutics, is a good buy. For example, gross profit margin measures Lexeo Therapeutics,'s profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Lexeo Therapeutics,'s profitability and make more informed investment decisions.
Basic technical analysis of Lexeo Stock
As of the 27th of March, Lexeo Therapeutics, secures the Risk Adjusted Performance of (0.03), mean deviation of 5.64, and Standard Deviation of 8.78. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lexeo Therapeutics,, as well as the relationship between them.Lexeo Therapeutics,'s insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lexeo Therapeutics, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lexeo Therapeutics,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lexeo Therapeutics, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lexeo Therapeutics,'s Outstanding Corporate Bonds
Lexeo Therapeutics, issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Lexeo Therapeutics, uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Lexeo bonds can be classified according to their maturity, which is the date when Lexeo Therapeutics, Common has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Lexeo Therapeutics,'s technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Lexeo Therapeutics,'s various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.11) | |||
| Mean Deviation | 5.64 | |||
| Coefficient Of Variation | (2,373) | |||
| Standard Deviation | 8.78 | |||
| Variance | 77.02 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.37) | |||
| Total Risk Alpha | (0.35) | |||
| Treynor Ratio | (0.12) | |||
| Maximum Drawdown | 42.37 | |||
| Value At Risk | (9.64) | |||
| Potential Upside | 9.3 | |||
| Skewness | 3.04 | |||
| Kurtosis | 17.29 |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.11) | |||
| Mean Deviation | 5.64 | |||
| Coefficient Of Variation | (2,373) | |||
| Standard Deviation | 8.78 | |||
| Variance | 77.02 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.37) | |||
| Total Risk Alpha | (0.35) | |||
| Treynor Ratio | (0.12) | |||
| Maximum Drawdown | 42.37 | |||
| Value At Risk | (9.64) | |||
| Potential Upside | 9.3 | |||
| Skewness | 3.04 | |||
| Kurtosis | 17.29 |
Consider Lexeo Therapeutics,'s intraday indicators
Lexeo Therapeutics, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Lexeo Therapeutics, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Lexeo Therapeutics, Corporate Filings
8K | 24th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 21st of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
| 13th of February 2025 Other Reports | ViewVerify |
Lexeo Stock media impact
Far too much social signal, news, headlines, and media speculation about Lexeo Therapeutics, that are available to investors today. That information is available publicly through Lexeo media outlets and privately through word of mouth or via Lexeo internal channels. However, regardless of the origin, that massive amount of Lexeo data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lexeo Therapeutics, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lexeo Therapeutics, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lexeo Therapeutics,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lexeo Therapeutics, alpha.
Lexeo Therapeutics, Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Lexeo Therapeutics, can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Lexeo Therapeutics, Corporate Management
| Ryan McHenry | VP Controller | Profile | |
| Rand Monaghan | Vice Finance | Profile | |
| Paul McCormac | Chief Officer | Profile | |
| Jordan MD | Cardiology Science | Profile | |
| Jenny Robertson | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexeo Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexeo Therapeutics,. If investors know Lexeo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexeo Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lexeo Therapeutics, is measured differently than its book value, which is the value of Lexeo that is recorded on the company's balance sheet. Investors also form their own opinion of Lexeo Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Lexeo Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexeo Therapeutics,'s market value can be influenced by many factors that don't directly affect Lexeo Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Lexeo Therapeutics,'s value and its price, as these two are different measures arrived at by various means. Investors typically determine if Lexeo Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexeo Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.